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Rheumatoid arthritis (RA) is a chronic inflammatory disease 
primarily affecting joints and their adjacent structures that 
leads to joint damage and deformity.1 Treatment of RA seeks 
to control both inflammation and pain and to reduce disabili-
ty related to RA by the proper use of disease modifying anti-
rheumatic drugs (DMARDs). Even though methotrexate re-
mains a cornerstone in the treatment of RA, remarkable 
advances in the therapeutic regimens for RA have been made 
in the past decades. Particularly, biologics targeting inflamma-
tory cytokines, such as tumor necrosis factor-alpha (TNF-α) 
and interleukin-6 (IL-6), that play a crucial role in RA patho-
genesis2 have ushered in a new era of RA management. Treat-
ment guidelines currently recommend the application of bio-
logics to patients who fail to respond to conventional DMARDs,3 
and the number of patients receiving biologics have substan-
tially increased in recent years.4
Hepatitis B virus (HBV) infection is one of the most com-
mon worldwide viral infections. Because chronic inflamma-
tion by HBV can provoke cirrhosis, liver failure, and even he-
patocellular carcinoma, HBV still remains as a major public 
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To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reacti-
vation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) neg-
ative and antibody to HBV core antigen (anti-HBc) positive, serologically]. HBsAg, anti-HBc, antibody to HBsAg (anti-HBs), and 
HBV DNA titers were measured in RA patients who had continuously received tocilizumab for more than 3 months. Patients were 
divided into two groups according to the presence of anti-HBc. Clinical and laboratory data, in addition to medications adminis-
tered along with tocilizumab during the treatment duration with tocilizumab, were compared between the two groups. HBV re-
activation was defined as the presence of HBV DNA in sera, and alterations in HBsAg, anti-HBc, and anti-HBs titers according to 
the use of tocilizumab were also evaluated. Fifteen of 39 patients (38.5%) had anti-HBc positivity, while 24 patients (61.5%) did 
not. There were no differences in demographic data, serologic classification, and variables related to tocilizumab between the an-
ti-HBc-positive and -negative groups. Comparison of the medications administered along with tocilizumab treatment revealed 
no meaningful differences. None of the patients experienced reactivation of HBV. In addition, in 15 patients with resolved HBV 
infection, no alterations in HBsAg, anti-HBc, and anti-HBs titers were observed with the use of tocilizumab. Tocilizumab may be 
applied to RA patients safely with few concerns for HBV reactivation, particularly in those with resolved HBV infection.
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health concern. Global epidemiologic studies now show that 
more than 2 billion individuals have been infected by HBV 
and more than 350 million people have chronic HBV infection.5 
Recently, there have been increasing demands for screening 
for HBV infection in the field of rheumatology, as patients re-
ceiving biologics are at risk of HBV reactivation.6,7 Among viral 
factors associated with HBV reactivation, chronic HBV infec-
tion and high baseline HBV DNA are likely to be meaningful 
risk factors.6 In addition, HBV reactivation can occur in patients 
with resolved HBV infection, which is defined as HBV surface 
antigen (HBsAg) negative and antibody to HBV core antigen 
(anti-HBc) positive, regardless of antibody to HBsAg (anti-
HBs).7,8 So far, HBV reactivation in RA patients has been mainly 
assessed in patients receiving TNF-α blockade, but rarely in 
those receiving IL-6 receptor antagonist (tocilizumab). Fur-
thermore, the safety of tocilizumab in regards to HBV reacti-
vation in resolved HBV infection remains unclear. Hence, in 
this study, we investigated whether the use of tocilizumab 
might be associated with HBV reactivation in RA patients, par-
ticularly in those with resolved HBV infection. 
We retrospectively reviewed the medical records of patients 
with RA receiving tocilizumab according to the following in-
clusion criteria: 1) patients diagnosed with RA according to the 
2010 American College of Rheumatology/European League 
Against Rheumatism classification criteria for RA9,10 at the Di-
vision of Rheumatology, Yonsei University College of Medi-
cine, Severance Hospital; 2) patients who had information on 
HBsAg, anti-HBc, and anti-HBs at the initiation of tocilizumab 
and who did not have HBsAg; 3) patients who were continu-
ously receiving tocilizumab for more than 3 months; and 4) 
patients who provided blood samples for the cross-sectional 
analysis of HBsAg, anti-HBc, anti-HBs, and HBV DNA with in-
formed consent forms at the time of study enrollment. This 
study was approved by the Institutional Review Board of Sev-
erance Hospital, and was conducted in accordance with the 
principles set forth in the Declaration of Helsinki (IRB approval 
number 4-2017-0761).
We collected information on age, gender, and disease dura-
tion as demographic data. Patients were classified as seroposi-
tive and seronegative RA according to the presence of rheuma-
toid factor and anti-citrullinated protein antibodies. Regarding 
tocilizumab usage, information on DAS28-ESR (disease activi-
ty score 28–erythrocyte sedimentation rate) on the initiation of 
tocilizumab, treatment duration, and the route of administra-
tion were also obtained. We also reviewed laboratory data for 
aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), ESR, and C-reactive protein (CRP), both at initiation of 
tocilizumab and at study enrollment.
We measured HBsAg, anti-HBc, and anti-HBs both at initia-
tion of tocilizumab and at study enrollment. Serum HBV DNA 
titers were measured only at study enrollment. Reactivation of 
HBV was defined as a serum HBV DNA titer above the lower 
detection limit.11 Serum levels of HBsAg, anti-HBc, and anti-
HBs were detected and interpreted using the Abbott Architect 
i4000 immunoassay system (Abbott Diagnostics, Chicago, IL, 
USA). Serum HBV DNA was measured by real-time PCR assay 
(cobas CAP/CTM System, Roche Molecular Diagnostics, Indi-
anapolis, IN, USA) with a lower detection limit of 15 IU/mL. 
We reviewed medications that were administered along with 
tocilizumab throughout the duration of tocilizumab treatment. 
We particularly calculated the cumulative dosages of gluco-
corticoid and methotrexate administered during the treatment 
duration of tocilizumab. In addition, as it is known that HBV 
reactivation is more common within the first 6 months after 
the start of immunosuppressive therapies, we also calculated 
the cumulative dosage of both drugs for the initial 6 months 
after tocilizumab initiation.12 
Continuous variables are presented as medians with inter-
quartile ranges, and categorical variables are expressed as fre-
quencies and percentages. Continuous variables were com-
pared using the Mann-Whitney U test, and categorical data 
were compared using the Chi-squared test or Fisher’s exact test, 
as appropriate. Comparison of serum titers of HBsAg, anti-
HBc, and anti-HBs at initiation of tocilizumab and those at study 
enrollment was performed using the Wilcoxon signed rank 
test. All statistical analyses were conducted using the SPSS pack-
age for Windows, version 21 (IBM Corp., Armonk, NY, USA). 
p-values <0.05 were considered statistically significant. 
The baseline characteristics of patients are described in Table 
1. The median age was 55.0, and 28 (71.8%) patients were fe-
male. The median disease duration before the initiation of to-
cilizumab was 61.7 months. Thirty-five (89.7%) patients were 
classified as seropositive RA, while only 4 patients were as sero-
negative RA. Median DAS-28 ESR score at initiation of tocili-
zumab was 7.0. The median treatment duration with tocili-
zumab was 10.8 months. 
Among the patients enrolled, 15 of 39 patients (38.5%) had 
anti-HBc. Since no patients had a history of chronic HBV in-
fection, none received antiviral therapy for hepatitis B prophy-
laxis. There were no differences in demographic data and se-
rologic classification between patients with and without anti-
HBc. Furthermore, variables related to tocilizumab did not 
differ between the two groups. In addition, patients with anti-
HBc exhibited anti-HBs positivity more frequently than those 
without, although the difference was not significant (80.0% vs. 
50.0%, p=0.093). Alterations in AST, ALT, ESR, and CRP over 
the duration of treatment with tocilizumab were not remark-
able (Table 1). 
To minimize the influence of other medications adminis-
tered along with tocilizumab on HBV reactivation, we com-
pared the frequencies of glucocorticoid and DMARDs and the 
cumulative dosages of glucocorticoid and methotrexate dur-
ing the treatment duration of tocilizumab. Among the medi-
cations administered, glucocorticoid was the most commonly 
used medication, followed by methotrexate and sulfasalazine 
in the both groups. We found no meaningful differences in 
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the frequencies of all medications between patients with and 
without anti-HBc. Furthermore, the cumulative dosages of 
both glucocorticoid and methotrexate and the cumulative dos-
ages of both drugs within the first 6 months after tocilizumab 
initiation also did not differ (Table 2).  
In this study, reactivation of HBV was defined as the presence 
of HBV DNA in sera. We measured HBV DNA at study enroll-
ment in all 39 patients regardless of anti-HBc; however, we 
could find no patient in whom serum HBV DNA was detected. 
Therefore, we concluded that the use of tocilizumab more than 
Table 1. Characteristics of Patients with RA and Comparison of Variables between Patients with and without Anti-HBc
Total patients 
(n=39)
Patients with anti-HBc 
(n=15)
Patients without anti-HBc 
(n=24)
p value
Demographic data
Age (yr) 55.0 (46.3−62.0) 57.0 (48.5−68.5) 50.0 (43.0−61.5) 0.141
Female gender    28 (71.8)    10 (66.7)    19 (79.2) 0.391
Disease duration (month) 61.7 (21.4−152.3) 52.7 (20.9−121.5) 67.7 (22.2−170.2) 0.729
Serologic classification 0.999
Seropositive RA    35 (89.7)    14 (93.3)    21 (87.5)
Seronegative RA      4 (10.3)      1 (6.7)      3 (12.5)
Tocilizumab
DAS-28 ESR at initiation   7.0 (6.4−7.4)   7.2 (6.5−7.4)   6.9 (6.3−7.5) 0.581
Treatment duration (month) 10.8 (6.2−23.7)   9.4 (5.7−25.8) 11.0 (6.3−23.5) 0.436
Route of tocilizumab 0.658
Intravenous    33 (84.6)    12 (80.0)    21 (87.5)
Subcutaneous      6 (15.4)      3 (20.0)      3 (12.5)
Laboratory data at initiation of tocilizumab
Anti-HBs positive    24 (61.5)    12 (80.0)    12 (50.0) 0.093
AST (IU/L) 16.0 (13.0−20.0) 16.0 (13.0−21.5) 17.0 (14.0−20.0) 0.795
ALT (IU/L) 15.0 (9.3−25.8) 14.0 (9.3−19.8) 16.0 (9.0−27.0) 0.654
ESR (mm/hr) 61.0 (40.5−77.8) 62.0 (48.3−76.3) 54.0 (39.0−78.0) 0.603
CRP (g/mL) 13.6 (4.9−28.3) 16.5 (8.0−53.0) 13.0 (3.7−27.1) 0.319
Laboratory data at study enrollment
AST (IU/L) 20.0 (17.0−27.0) 20.0 (17.0−25.3) 20.5 (16.5−27.5) 0.977
ALT (IU/L) 23.0 (14.0−29.8) 22.0 (15.5−29.5) 24.0 (13.0−29.5) 0.840
ESR (mm/hr)   9.0 (3.0−21.5) 12.0 (4.5−21.0)   7.5 (2.5−21.0) 0.347
CRP (g/mL)   0.2 (0.1−0.8)   0.3 (0.2−0.9)   0.2 (0.1−0.7) 0.178
Anti-HBc, positive antibody to HBV core antigen; RA, rheumatoid arthritis; DAS, disease activity score; ESR, erythrocyte sedimentation rate; Anti-HBs, antibody 
to HBsAg; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein.
Values are expressed as the median (interquartile range) or number (percentage).
Table 2. Comparison of Medication Administered along with Tocilizumab between Patients with and without Anti-HBc
Medications Patients with anti-HBc (n=15) Patients without anti-HBc (n=24) p value
Glucocorticoid        14 (93.3)        21 (87.5) 0.999
Cumulative glucocorticoid dosage (mg)* 1015.0 (506.3−1760.0) 1295.0 (519.1−3073.8) 0.419
Cumulative glucocorticoid dosage within the first 6 months (mg)*   775.0 (340.0−905.0)   800.0 (452.5−1061.3) 0.523
Methotrexate        11 (73.3)        17 (70.8) 0.999
Cumulative methotrexate dosage (mg)†   557.1 (294.7−940.7)   689.6 (444.6−1156.8) 0.458
Cumulative methotrexate dosage within the first 6 months (mg)†   338.6 (266.1−490.0)   316.4 (240.0−379.8) 0.312
Leflunomide          0 (0.0)          2 (8.3) 0.514
Hydroxychloroquine          1 (6.7)          6 (25.0) 0.216
Sulfasalazine          3 (20.0)          7 (29.2) 0.711
Tacrolimus          1 (6.7)          2 (8.3) 0.999
Anti-HBc, positive antibody to HBV core antigen.
Values are expressed as the median (interquartile range) or number (percentage).
*The cumulative glucocorticoid dosage was represented in prednisolone equivalent dosage and was calculated in those treated with glucocorticoids, †The cu-
mulative methotrexate dosage was calculated in those treated with methotrexate.
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3 months was not associated with HBV reactivation. 
We also evaluated whether tocilizumab is associated with 
alterations in the titers of HBsAg, anti-HBc, and anti-HBs in 
15 patients with resolved HBV infection. When we compared 
HBsAg, anti-HBc, and anti-HBs titers between at initiation of 
tocilizumab and at study enrollment, we could find no signifi-
cant differences between the two (Fig. 1). 
In this study, we investigated whether the use of tocilizumab 
might be associated with HBV reactivation in RA patients, par-
ticularly in those with resolved HBV infection. We found that 
tocilizumab treatment with the median treatment duration of 
9.4 months was not associated with HBV reactivation or the 
presence of HBV DNA in sera. Moreover, the use of tocilizumab 
did not contribute to alterations in HBsAg, anti-HBc, and anti-
HBs titers in patients with resolved HBV infection. There is 
discordance between our study and previous studies. Previ-
ous studies reported that patients with autoimmune diseases 
accompanied by lower anti-HBs titer exhibit a higher rate of 
HBV reactivation13 and that TNF-α inhibitor treatment is asso-
ciated with decreases in anti-HBs titers in patients with inflam-
matory arthritis.14 However, in the present study, no patients 
with resolved HBV infection experienced HBV reactivation, 
and furthermore, alterations in the titers of variables related to 
HBV did not depend on the use of tocilizumab, unlike TNF-α 
inhibitor. 
Worldwide, HBV infection is the most common cause of ch-
ronic liver disease. South Korea is known as an endemic area of 
chronic HBV infection.15 Although successful implementation 
of national vaccination programs to eliminate HBV infection 
has shown progress in decreasing the prevalence of HBsAg 
positivity in the general population, South Korea is still classi-
fied as an intermediate HBV endemic area.16 In regions with 
intermediate to high risk of HBV infection, the assessment of 
HBV reactivation following the use of biologics stands to be a 
clinically important issue, as RA patients often experience ele-
vated liver enzymes during treatment. Because a majority of 
RA patients are treated with a combination of medications, 
including glucocorticoids, DMARDs, and biologics, it is crucial 
to discriminate between viral reactivation and drug induced 
liver injury. The risk of HBV reactivation does not seem to be 
high in patients with resolved HBV infection,6 although evi-
dence further indicates that biologics therapy could be associ-
ated with HBV reactivation. In a recent systematic review, the 
estimated proportion of patients experiencing HBV reactiva-
tion in those with resolved HBV infection during TNF-α treat-
ment was 1.7%.17 However, the risk of HBV reactivation in re-
solved HBV infection due to the use of tocilizumab remains a 
debate: a literature review suggested that 8.6% of patients treat-
ed with tocilizumab suffered from HBV reactivation,18 while in 
a recent study, HBV reactivation was not reported in patients 
treated with tocilizumab.19,20 We assume that this discrepancy 
might be attributable to differences in both the definition of 
HBV reactivation and geographic and ethnic features. In this 
regard, data regarding the safety of tocilizumab in Korean pa-
tients with RA regardless of resolved HBV infection would be 
needed; however, there are no data thereon. For these reasons, 
we deduced that tocilizumab may not participate in provok-
ing HBV reactivation in Korean patients with RA regardless of 
anti-HBc positivity and that, furthermore, it may not contrib-
ute to changes in the titers of variables related to HBV in pa-
tients with resolved HBV infection.  
The strength of this study is that it is the first to demonstrate 
the safety of tocilizumab in RA patients, particularly in those 
with resolved HBV infection, in Korea. Because anti-viral agents 
should be applied to all patients with chronic HBV infection 
before the use of biologics, in this study, we focused on HBV 
reactivation in patients with resolved HBV infection. However, 
our study has several limitations. First, we had no information 
on the presence of HBV DNA at initiation of tocilizumab due to 
the absence of HBsAg in all patients. Second, the number of 
patients treated with tocilizumab was relatively small with a 
short follow-up duration. This might have affected the nega-
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Fig. 1. Alterations in the titers of HBsAg (A), anti-HBc (B), and anti-HBs (C) in patients with resolved HBV infection. There were no meaningful differ-
ences in the titers of HBsAg, anti-HBc, and anti-HBs in 15 patients with resolved HBV infection at initiation of tocilizumab and at study enrollment. 
HBsAg, HBV surface antigen; Anti-HBc, positive antibody to HBV core antigen; Anti-HBs, antibody to HBsAg; HBV, hepatitis B virus.
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tive results that were observed in this study. In addition, it is 
unclear whether tocilizumab is more advantageous to TNF-α 
inhibitors in terms of HBV reactivation, especially in those 
with resolved HBV infection. Future studies with a larger num-
ber of patients treated with tocilizumab will clarify the link be-
tween the use of tocilizumab and HBV reactivation in RA pa-
tients with resolved HBV infection. 
In conclusion, the use of tocilizumab was not associated 
with HBV reactivation in RA patients, particularly in those with 
resolved HBV infection, in Korea. We suggest that tocilizumab 
may be safely applied in terms of HBV reactivation to RA pa-
tients with HBsAg negativity and anti-HBc positivity, regard-
less of anti-HBs. 
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